Leslie Shane Jones
Known title: EVP & Chief Financial OfficerCIK: 0001959469
Associated companies
Transaction History
| NATR | ▲ Buy | Option Exercise | 4,004 | $0 | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,756 | $46K | 5/5/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 2,484 | $0 | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,090 | $28K | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 3,512 | $95K | 4/20/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 2,341 | $58K | 3/11/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 2,847 | $71K | 3/10/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 2,002 | $0 | 3/6/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 878 | $22K | 3/6/2026 | View on chart |
| NATR | ▲ Buy | Grant | 11,798 | $296K | 3/6/2026 | View on chart |
| NATR | ▼ Sell | Other | 11,798 | — | 3/6/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 4,004 | $0 | 11/4/2025 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,756 | $24K | 11/4/2025 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 2,343 | $34K | 3/11/2025 | View on chart |
| NATR | ▲ Buy | Grant | 19,474 | $287K | 3/10/2025 | View on chart |
| NATR | ▲ Buy | Grant | 9,925 | $150K | 12/19/2024 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 2,747 | $53K | 4/20/2024 | View on chart |
| NATR | ▲ Buy | Grant | 16,010 | $0 | 3/11/2024 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 5,965 | $106K | 12/19/2023 | View on chart |
| NATR | ▲ Buy | Grant | 24,022 | $0 | 4/20/2023 | View on chart |
| NATR | ▲ Buy | Grant | 67,818 | $0 | 12/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nature's Sunshine Q2 Earnings Reviewed Against Peers
A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.
Nature's Sunshine Q2 Earnings Reviewed Against Peers. A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.